美国

我们是谁

  • 4 月 5, 2022
    QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
  • 4 月 5, 2022
    评估 pING-hHER3FL 的免疫原性
  • 4 月 5, 2022
    NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    用于治疗胃肠道腺癌的疫苗（Ad5.F35-hGCC-PADRE）
  • 4 月 5, 2022
    Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究
  • 4 月 5, 2022
    Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
  • 4 月 5, 2022
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
  • 4 月 5, 2022
    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers